This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Background and Date of Approval
Lamivudine + Nevirapine + Stavudine is a combination of three antiretroviral medicines. FDA approved it initially on 11th August 2006 for its medical use.
Mechanism of Action of undefined
Lamivudine + Nevirapine + Stavudine is a combination of three anti-retroviral medicines. Lamivudine and stavudine tablet works by inhibiting the reverse transcriptase enzyme of HIV, restricting viral genome replication, and reducing the production of new infectious viral particles. It mainly interferes with reverse transcription and inhibits the spread of HIV. Nevirapine binds directly to reverse transcriptase (RT) and blocks RNA-dependent and DNA-dependent polymerase activities by disrupting the enzyme.
Uses of undefined
Lamivudine + Nevirapine + Stavudine is available as a tablet. Lamivudine and Stavudine belong to the class of medications called nucleoside/nucleotide reverse transcriptase inhibitors. Nevirapine belongs to the class of medication called non-nucleoside reverse transcriptase inhibitors. It is used to treat HIV-1 infection.
undefined Drug administaration and Dosage available
It is an orally available prescription drug. Your doctor will decide the dose and duration of Lamivudine + Nevirapine + Stavudine based on the disease condition and other factors such as body weight and age. Always take this medicine as prescribed by your doctor. Take the tablet at the same time, with or without food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with a glass of water.
Warnings, Precautions and Side Effects of undefined
This drug is indicated to cause severe bone marrow depression. Routine blood tests will be taken to monitor your complete blood counts. This medicine may cause a severe skin rash. Inform your physician if you develop any rashes, redness, or swelling in the skin after taking Lamivudine + Nevirapine + Stavudine. This medicine is not intended for pregnant and breastfeeding women. Liver failure may occur on long-term use of this medicine. Inform your doctor if you have any liver diseases prior to the therapy.
Do not take Lamivudine + Nevirapine + Stavudine if you are allergic to Lamivudine + Nevirapine + Stavudine, or any of the other ingredients, or if you are pregnant or breastfeeding. Inform your physician if you have liver problems, hepatitis infection, kidney diseases, or undergoing dialysis. Notify your physician if you have any active skin conditions such as rash.
Inform your healthcare provider about all your medicines, including prescription, over-the-counter, nutritional, and supplements and herbal products. Certain medications interact with Lamivudine + Nevirapine + Stavudine, reducing its effectiveness by causing undesirable side effects.
The common side effects of skin rash, nausea, vomiting, loss of appetite, diarrhea, and abdominal pain. Serious side effects are decreased/increased white blood cells or red blood cells, liver injury, and severe skin reaction.
Word Of Advice
Do not store above 25°C. Protect the medicine from light and excessive moisture. Keep the medicine out of reach of children and pets. If you forgot to take the tablet, take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose. Follow your doctor’s instructions with respect to high-risk activities such as unprotected sex and personal items that can have blood or body fluids on them, like toothbrushes, razor blades, and needles. Always practice safe sex by using a condom to lower the chance of sexual contact with semen, vaginal secretions, or blood. These medications do not cure HIV or AIDS, and you can still transmit the virus to others during therapy with these medications.
Frequently Asked Question
- KD Tripathi, Antiviral Drugs (Anti-retrovirus), Essentials of Medical Pharmacology, 8th Edition, 2019, 860-872.
- Sharon Safrin, Antiviral Agents, Lange’s Basic and Clinical Pharmacology, 14th Edition, 2018, 863-894.
- Lamivudine, Stavudine and Nevirapine Tablets (Lamivudine 150 Mg, Stavudine 30 Mg and Nevirapine 200 Mg) .; Revised 2010. Accessed May 18, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/pepfar/022177PI.pdf
- Siegfried N, van Deventer PJ, Mahomed FA, Rutherford GW. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. Cochrane Database of Systematic Reviews. Published online April 19, 2006. doi:https://doi.org/10.1002/14651858.cd004535.pub2
The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.